Obesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline
Journal of Neurochemistry · 2024
DOI: 10.1111/jnc.15900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, 2024. Verfasst von Thea Anderson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Institute, Georgia State University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Obesity, Brain. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: NIDDK NIH HHS, NIA NIH HHS, Georgia Clinical and Translational Science Alliance.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is the most common form of dementia. Obesity in middle age increases AD risk and severity, which is alarming given that obesity prevalence peaks at middle age and obesity rates are accelerating worldwide. Midlife, but not late‐life obesity increases AD risk, suggesting that this interaction is specific to preclinical AD. AD pathology begins in middle age, with accumulation of amyloid beta (Aβ), hyperphosphorylated tau, metabolic decline, and neuroinflammation occurring decades before cognitive symptoms appear. We used a transcriptomic discovery approach in young adult (6.5 months old) male and female TgF344‐AD rats that overexpress mutant human amyloid precursor protein and presenilin‐1 and wild‐type (WT) controls to determine whether inducing obesity with a high‐fat/high‐sugar “Western” diet during preclinical AD increases brain metabolic dysfunction in dorsal hippocampus (dHC), a brain region vulnerable to the effects of obesity and early AD. Analyses of dHC gene expression data showed dysregulated mitochondrial and neurotransmission pathways, and up‐regulated genes involved in cholesterol synthesis. Western diet amplified the number of genes that were different between AD and WT rats and added pathways involved in noradrenergic signaling, dysregulated inhibition of cholesterol synthesis, and decreased intracellular lipid transporters. Importantly, the Western diet impaired dHC‐dependent spatial working memory in AD but not WT rats, confirming that the dietary intervention accelerated cognitive decline. To examine later consequences of early transcriptional dysregulation, we measured dHC monoamine levels in older (13 months old) AD and WT rats of both sexes after long‐term chow or Western diet consumption. Norepinephrine (NE) abundance was significantly decreased in AD rats, NE turnover was increased, and the Western diet attenuated the AD‐induced increases in turnover. Collectively, these findings indicate obesity during prodromal AD impairs memory, potentiates AD‐induced metabolic decline likely leading to an overproduction of cholesterol, and interferes with compensatory increases in NE transmission. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuroscience Institute, Georgia State University, Atlanta, Georgia, USA.
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA.
- Department of Psychology, Georgia State University, Georgia, USA.
ORCID-Profile: Thea Anderson, Michael A Kelberman, Nanxi Guo, Marise B Parent
Förderung
- NIDDK NIH HHS
- NIA NIH HHS
- Georgia Clinical and Translational Science Alliance
- Georgia State University
- NIMH NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Mental Health
- National Institute on Aging
Zitieren
APA
Anderson, T., Sharma, S., Kelberman, M. A., Ware, C., Guo, N., Qin, Z., Weinshenker, D., & Parent, M. B. (2024). Obesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15900
Vancouver
Anderson T, Sharma S, Kelberman MA, Ware C, Guo N, Qin Z, et al. Obesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline. Journal of Neurochemistry. 2024. doi:10.1111/jnc.15900
BibTeX
@article{Anderson2024,
author = {Anderson, Thea and Sharma, Sumeet and Kelberman, Michael A and Ware, Christopher and Guo, Nanxi and Qin, Zhaohui and Weinshenker, David and Parent, Marise B},
title = {Obesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline},
journal = {Journal of Neurochemistry},
year = {2024},
doi = {10.1111/jnc.15900}
}
EUVIMED